About This Event

Crescent Biopharma, Inc. (Nasdaq: CBIO), a clinical-stage biotechnology company advancing the next wave of therapies for people living with cancer, will visit the Nasdaq MarketSite in Times Square. Crescent's oncology pipeline includes its potentially best-in-class PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs), which are being developed as single agents and as part of combination regimens to treat a range of solid tumors. The visit highlights Crescent’s continued momentum across its oncology portfolio.

In honor of the occasion, Joshua Brumm, Chief Executive Officer rings the Closing Bell.